BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34510663)

  • 1. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
    Murase Y; Ono H; Ogawa K; Yoshioka R; Ishikawa Y; Ueda H; Akahoshi K; Ban D; Kudo A; Tanaka S; Tanabe M
    Cancer Sci; 2021 Nov; 112(11):4641-4654. PubMed ID: 34510663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor.
    Liu M; Yu H; Huo L; Liu J; Li M; Zhou J
    Biochem Pharmacol; 2008 Jul; 76(2):169-78. PubMed ID: 18539263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
    Purcell JW; Davis J; Reddy M; Martin S; Samayoa K; Vo H; Thomsen K; Bean P; Kuo WL; Ziyad S; Billig J; Feiler HS; Gray JW; Wood KW; Cases S
    Clin Cancer Res; 2010 Jan; 16(2):566-76. PubMed ID: 20068098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
    Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma.
    Gampa G; Kenchappa RS; Mohammad AS; Parrish KE; Kim M; Crish JF; Luu A; West R; Hinojosa AQ; Sarkaria JN; Rosenfeld SS; Elmquist WF
    Sci Rep; 2020 Apr; 10(1):6524. PubMed ID: 32300151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.
    Wang F; Good JA; Rath O; Kaan HY; Sutcliffe OB; Mackay SP; Kozielski F
    J Med Chem; 2012 Feb; 55(4):1511-25. PubMed ID: 22248262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models.
    Good JA; Wang F; Rath O; Kaan HY; Talapatra SK; Podgórski D; MacKay SP; Kozielski F
    J Med Chem; 2013 Mar; 56(5):1878-93. PubMed ID: 23394180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Snapshots" of ispinesib-induced conformational changes in the mitotic kinesin Eg5.
    Kaan HY; Major J; Tkocz K; Kozielski F; Rosenfeld SS
    J Biol Chem; 2013 Jun; 288(25):18588-98. PubMed ID: 23658017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
    Nagarajan S; Skoufias DA; Kozielski F; Pae AN
    J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5.
    Sun XD; Shi XJ; Sun XO; Luo YG; Wu XJ; Yao CF; Yu HY; Li DW; Liu M; Zhou J
    Acta Pharmacol Sin; 2011 Dec; 32(12):1543-8. PubMed ID: 21986572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
    Xing ND; Ding ST; Saito R; Nishizawa K; Kobayashi T; Inoue T; Oishi S; Fujii N; Lv JJ; Ogawa O; Nishiyama H
    Asian J Androl; 2011 Mar; 13(2):236-41. PubMed ID: 21297652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
    Sheth PR; Basso A; Duca JS; Lesburg CA; Ogas P; Gray K; Nale L; Mannarino AF; Prongay AJ; Le HV
    Biochemistry; 2009 Nov; 48(46):11045-55. PubMed ID: 19824700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma.
    Ding S; Zhao Z; Sun D; Wu F; Bi D; Lu J; Xing N; Sun L; Wu H; Ding K
    Tumour Biol; 2014 Aug; 35(8):7659-68. PubMed ID: 24801905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structure of the ternary Eg5-ADP-ispinesib complex.
    Talapatra SK; Schüttelkopf AW; Kozielski F
    Acta Crystallogr D Biol Crystallogr; 2012 Oct; 68(Pt 10):1311-9. PubMed ID: 22993085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands.
    Łomzik M; Hanif M; Budniok A; Błauż A; Makal A; Tchoń DM; Leśniewska B; Tong KKH; Movassaghi S; Söhnel T; Jamieson SMF; Zafar A; Reynisson J; Rychlik B; Hartinger CG; Plażuk D
    Inorg Chem; 2020 Oct; 59(20):14879-14890. PubMed ID: 33003697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo.
    Jungwirth G; Yu T; Cao J; Eddine MA; Moustafa M; Warta R; Debus J; Unterberg A; Abdollahi A; Herold-Mende C
    Cancer Lett; 2021 May; 506():1-10. PubMed ID: 33652084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.
    Wang Y; Wu X; Du M; Chen X; Ning X; Chen H; Wang S; Liu J; Liu Z; Li R; Fu G; Wang C; McNutt MA; Zhou D; Yin Y
    Oncotarget; 2017 Jun; 8(26):42510-42524. PubMed ID: 28489567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
    Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
    Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
    Koller E; Propp S; Zhang H; Zhao C; Xiao X; Chang M; Hirsch SA; Shepard PJ; Koo S; Murphy C; Glazer RI; Dean NM
    Cancer Res; 2006 Feb; 66(4):2059-66. PubMed ID: 16489005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.